Cholic Acid-2,2,4,4-D4 (Cholic Acid-2,2,4,4-D4) by Sigma-Aldrich Corporation: new drug for further processing listing
Cholic Acid-2,2,4,4-D4 (Cholic Acid-2,2,4,4-D4) by Sigma-Aldrich Corporation: new drug for further processing listing. Dated 35 days ago, it serves as a historical benchmark. Score 15/100. As of 2026-11-04, from U.S. FDA National Drug Code (NDC) Directory via openFDA.
Data as of · Compiled by Zalwin from U.S. FDA National Drug Code (NDC) Directory via openFDA
Free preview: all 9 published fields of this record are shown below. Locked: 106 related FdaNdcDirectoryPulse records and the 5-column CSV export.
| Field | Value |
|---|---|
| Generic name | Cholic Acid-2,2,4,4-D4 |
| NDC | 17445-6888 |
| Labeler | Sigma-Aldrich Corporation |
| Product type | DRUG FOR FURTHER PROCESSING |
| Approval pathway | DRUG FOR FURTHER PROCESSING |
| Dosage form | POWDER |
| Active ingredients | CHOLIC ACID-2,2,4,4-D4 1 g/g |
| Marketing start | 2026-10-01 |
| Package configurations | 1 |
| Peer records CSV (107 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Cholic Acid-2,2,4,4-D4 (Cholic Acid-2,2,4,4-D4) by Sigma-Aldrich Corporation
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Cholic Acid-2,2,4,4-D4 (Cholic Acid-2,2,4,4-D4) by Sigma-Aldrich + all 107 records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Product · Labeler · Pathway · Form · Listed · official source URL
- Source agency: U.S. FDA National Drug Code (NDC) Directory via openFDA
- Record date: 2026-10-01
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top FdaNdcDirectoryPulse records (DRUG FOR FURTHER PROCESSING first): Lutetium (Lu 177) chloride (Lutetium (Lu 177) chloride) by C · Olibanum 1X (Olibanum 1X) by US Tinctures, LLC · ACYCLOVIR (ACYCLOVIR) by Isomedix Operations Inc · Water (Water) by Siegfried Hameln GmbH · Exosomes (Exosomes) by Regenerative Cell Research Institute · Browse all by state and category →
LIVE PUBLIC DATA Source: U.S. FDA National Drug Code (NDC) Directory via openFDA · Last refreshed: Wed, 04 Nov 2026 18:12:05 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Cholic Acid-2,2,4,4-D4 (Cholic Acid-2,2,4,4-D4) by Sigma-Aldrich Corporation and 107 DRUG FOR FURTHER PROCESSING peers
- DRUG FOR FURTHER PROCESSING FdaNdcDirectoryPulse records like this one: 107
- Timing: Low: older than 30 days
- Estimated pipeline if you contact every DRUG FOR FURTHER PROCESSING peer: $21,400 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
15 / 100 Launch Signal Score
What is the FdaNdcDirectoryPulse record for Cholic Acid-2,2,4,4-D4 (Cholic Acid-2,2,4,4-D4) by Sigma-Aldrich Corporation?
Cholic Acid-2,2,4,4-D4 by Sigma-Aldrich Corporation: new drug for further processing listing (DRUG FOR FURTHER PROCESSING) starting 2026-10-01.
How does Cholic Acid-2,2,4,4-D4 (Cholic Acid-2,2,4,4-D4) by Sigma-Aldrich Corporation compare to other FdaNdcDirectoryPulse records?
It is 35 days old, still within a typical 45-day follow-up window. Its Launch Signal Score of 15/100 is modest; treat it as background rather than a priority.
Cholic Acid-2,2,4,4-D4 (Cholic Acid-2,2,4,4-D4) by Sigma-Aldrich Corporation vs. top 3 peers
| Organization | Location | Record date |
|---|---|---|
| Cholic Acid-2,2,4,4-D4 (Cholic Acid-2,2,4,4-D4) by Sigma-Aldrich Corporation | DRUG FOR FURTHER PROCESSING | 2026-10-01 |
| Water (Water) by Siegfried Hameln GmbH | DRUG FOR FURTHER PROCESSING | 2026-10-19 |
| Donanemab (Donanemab) by BSP Pharmaceuticals S.p.A. | DRUG FOR FURTHER PROCESSING | 2026-09-22 |
| apitegromab (apitegromab) by Catalent Pharma Solutions, LLC | DRUG FOR FURTHER PROCESSING | 2026-09-11 |
Related records
- Ifosfamide
- Liquid Oxygen
- Rifadin
- Oxygen
- Water (Water) by Siegfried Hameln GmbH: new drug for further processing listing
- Donanemab (Donanemab) by BSP Pharmaceuticals S.p.A.: new drug for further processing listing
- apitegromab (apitegromab) by Catalent Pharma Solutions, LLC: new drug for further processing listing
- zilganersen (zilganersen) by Patheon Italia S.p.A.: new drug for further processing listing
- teduglutide (teduglutide) by Patheon Italia S.p.A.: new drug for further processing listing
- rusfertide (rusfertide) by Patheon Italia S.p.A.: new drug for further processing listing
- rusfertide (rusfertide) by Patheon Italia S.p.A.: new drug for further processing listing
- rusfertide (rusfertide) by Patheon Italia S.p.A.: new drug for further processing listing
How to monitor Cholic Acid-2,2,4,4-D4 (Cholic Acid-2,2,4,4-D4) by Sigma-Aldrich Corporation and peer other records
Get new FdaNdcDirectoryPulse records like Cholic Acid-2,2,4,4-D4 (Cholic Acid-2,2,4,4-D4) by Sigma-Aldrich Corporation by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new listings in your categories
FdaNdcDirectoryPulse emails new drug listings matching your pathway and product type.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
Listing data comes from the FDA NDC directory via openFDA; a listing is not an FDA approval or endorsement and may be updated or withdrawn. Informational only; not medical advice.